PharmaCord Boosts Leadership Team, Appoints Rob Brown As Chief Growth Officer

PharmaCord LLC, a prominent player in providing patient support services to the pharmaceutical sector, has recently announced a strategic move in its leadership team by appointing Rob Brown as the Chief Growth Officer. With a tenure starting in June 2021 as the Vice President of Strategic Accounts, Brown is set to take the helm of the business development and marketing divisions. His role will be pivotal in propelling PharmaCord's growth, focusing on developing and implementing strategies that aim to enhance the company's market position as a leading patient services partner.

Nitin Sahney, the founder and CEO of PharmaCord, praised Brown's significant contributions and leadership qualities. "Rob has been a driving force behind PharmaCord’s success, demonstrating exceptional leadership and vision since joining our team," Sahney remarked. His expertise is expected to be instrumental in leading the company's expansion efforts within the pharmaceutical industry.

This appointment underscores PharmaCord's dedication to investing in its sales and marketing functions as part of its broader strategy for sustained growth and maintaining a client-centric approach. Brown brings over two decades of experience in driving strategic initiatives and supporting distribution and commercialization for pharmaceutical and biotech partners. His previous roles include significant positions at McKesson, CVS, Omnicare, and Cardinal Health, where he was responsible for operational excellence and market share growth.

Before his time at PharmaCord, Brown held the position of Vice President & General Manager at McKesson’s pharmacy services, overseeing Biologics specialty pharmacy and RxCrossroads program pharmacy operations. Additionally, he managed the commercialization services business of Omnicare Specialty Care Group, which includes RxCrossroads and Advanced Care Scripts. Brown's academic background includes a Bachelor of Arts in English from The College of William and Mary.

About PharmaCord: PharmaCord acts as a bridge between drug manufacturers and patients, simplifying the therapeutic journey for patients through its proprietary technology suite, PharmaCord Lynk™, and its non-commercial pharmacy, PharmaCord Scripts™. The company's mission is to enhance patients' access to and adherence to vital medications, thereby improving commercial outcomes for life sciences companies. For more information about PharmaCord’s contributions to the pharmaceutical industry, visit pharmacord.com.

With this strategic appointment, PharmaCord is poised to further solidify its position in the industry by delivering innovative solutions that meet the evolving needs of clients and patients alike. Rob Brown's extensive experience and proven track record in business development and operational management are expected to drive significant growth for PharmaCord in the coming years.